Effect of Low Dose Galactose on Glycaemia and Glucose Kinetics
EFFECT OF LOW DOSE GALACTOSE ON GLYCAEMIA AND GLUCOSE KINETICS
University of Bath
25 participants
Jan 1, 2026
INTERVENTIONAL
Conditions
Summary
This project will establish the degree to which adding low-dose galactose to a meal can control blood sugar levels. People will consume standardised glucose drinks (75g glucose, as an oral glucose tolerance test). People will consume these with and without the addition of galactose, and with the addition of another sugar (fructose) for an extra comparison. We will use state-of-the-art labelling methods (dual stable isotope technology) to follow what happens to the glucose that is ingested and understand what happens to sugar being released by the liver and sugar being taken up by other tissues like the muscles. These methods can tell us how the addition of galactose can control blood sugar levels. For example, the galactose could slow down the appearance of glucose from the gut and/or liver released into the blood, or it could increase the disappearance of glucose from the blood into muscles. We will measure the appearance of our label on exhaled breath, which will establish whether ingested sugar is stored, or burned as fuel. We will also explore other potential ways in which galactose might control blood sugar levels by measuring key hormones and metabolites that contribute to blood sugar control (for example, insulin, fatty acids, and incretin hormones which potentiate insulin secretion). This additional evidence of how galactose can control blood sugar levels will provide the understanding required to best make use of this approach across a variety of settings.
Eligibility
Inclusion Criteria3
- Age: 18 years and above;
- Normoglycaemic (fasting glucose <6.1 mmol/L)
- Body mass index: 18.5-30 kg/m2
Exclusion Criteria9
- weight instability (>5% change within last 3 months);
- pregnant or lactating;
- following a very low-carbohydrate (ketogenic) diet;
- diagnosis of diabetes or prediabetes, or any other metabolic disease;
- dietary intolerances or allergies, or to any other study procedures;
- disorders in the ability to metabolise galactose or fructose (e.g., galactosemias);
- diagnosis of any gastrointestinal disorders;
- any other condition/medications that could introduce bias;
- unable to understand and follow study procedures
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
7.5 g galactose
7.5 g fructose
75 g glucose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07599683